Advertisement

Archives of Virology

, Volume 154, Issue 9, pp 1539–1544 | Cite as

ST1859 reduces prion infectivity and increase survival in experimental scrapie

  • Laura Colombo
  • Paola Piovesan
  • Orlando Ghirardi
  • Mario Salmona
  • Gianluigi Forloni
Brief Report

Abstract

On the basis of the structural homologies between ST1859 (1[(2-hydroxy-1-naphtyl)methyl]-2-naphthol) and the anti-prion agents and its anti-amyloidogenic activity, we tested whether this molecule altered the biochemical properties of aggregates formed in vitro by synthetic prion peptides and affected prion infectivity in experimental scrapie. Co-incubation of ST1859 with the peptides PrP 106–126 and PrP 82–146 reduced their fibrillogenic capacity and their resistance to digestion with protease K. Hamsters inoculated with the ST1859-treated homogenate showed a significant delay in the onset of clinical signs of disease and longer survival. Survival was also significantly longer in infected hamsters treated peripherally with ST1859 for the whole post-inoculation period until the onset of clinical symptoms. Similar results were found with the analogue ST1745. Our data indicate that ST1859 reduces prion infectivity and can exert a therapeutic effect in experimental scrapie.

Keywords

Median Survival Time Prion Protein Prion Disease Scrapie Prion Infectivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Abdul HM, Calabrese V, Calvani M, Butterfield DA (2006) Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1–42-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s disease. J Neurosci Res 84:398–408PubMedCrossRefGoogle Scholar
  2. 2.
    Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C et al (2006) Positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clin Pharmacol Ther 80:216–227PubMedCrossRefGoogle Scholar
  3. 3.
    Caramelli M, Ru G, Acutis P, Forloni G (2006) Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances. CNS Drugs 20:15–28PubMedCrossRefGoogle Scholar
  4. 4.
    De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, Forloni G, Tagliavini F, Salmona M (2008) The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 3:e1888PubMedCrossRefGoogle Scholar
  5. 5.
    Fioriti L, Angeretti N, Colombo L, De Luigi A, Colombo A, Manzoni C, Morbin M, Tagliavini F, Salmona M, Chiesa R, Forloni G (2007) Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein. J Neurosci 27:1576–1583PubMedCrossRefGoogle Scholar
  6. 6.
    Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M et al (2002) Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 99:10849–10854PubMedCrossRefGoogle Scholar
  7. 7.
    Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487:404–407PubMedCrossRefGoogle Scholar
  8. 8.
    Forloni G, Angeretti N, Smiroldo S (1994) Neuroprotective activity of acetyl-l-carnitine: studies in vitro. J Neurosci Res 37:92–96PubMedCrossRefGoogle Scholar
  9. 9.
    Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F (1993) Neurotoxicity of a prion protein fragment. Nature 362:543–546PubMedCrossRefGoogle Scholar
  10. 10.
    Forloni G, Varì MR, Colombo L, Bugiani O, Tagliavini F, Salmona M (2003) Prion diseases: time for a therapy? Curr Med Chem Immun Endocr Metab Agents 3:185–197CrossRefGoogle Scholar
  11. 11.
    Forloni G, Salmona M, Marcon G, Tagliavini F (2009) Tetracycline and prion infectivity. Infect Disord Drug Targets 9:23–30PubMedGoogle Scholar
  12. 12.
    Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98:9836–9841PubMedCrossRefGoogle Scholar
  13. 13.
    Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG et al (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 92:2959–2963PubMedCrossRefGoogle Scholar
  14. 14.
    Montgomery SA, Thal LJ, Amrein R (2003) Meta-analysis of double blind randomized controlled clinical trials of acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol 18:61–71PubMedCrossRefGoogle Scholar
  15. 15.
    Priola SA, Raines A, Caughey WS (2000) Porphyrin and phthalocyanine antiscrapie compounds. Science 287:1503–1506PubMedCrossRefGoogle Scholar
  16. 16.
    Prusiner SB (2001) Shattuck lecture—neurodegenerative diseases and prions. N Engl J Med 344:1516–1526PubMedCrossRefGoogle Scholar
  17. 17.
    Piccardo P, Dlouhy SR, Lievens PM, Young K, Bird TD, Nochlin D, Dickson DW, Vinters HV, Zimmerman TR et al (1998) Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol 57:979–988PubMedCrossRefGoogle Scholar
  18. 18.
    Salmona M, Morbin M, Massignan T, Colombo L, Mazzoleni G, Capobianco R, Diomede L, Thaler F, Mollica L et al (2003) Structural properties of Gerstmann–Straussler–Scheinker disease amyloid protein. J Biol Chem 278:48146–48153PubMedCrossRefGoogle Scholar
  19. 19.
    Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P et al (1991) Long-term acetyl-l-carnitine treatment in Alzheimer’s disease. Neurology 41:1726–1732PubMedGoogle Scholar
  20. 20.
    Stewart LA, Rydzewska LHM, Keogh GF, Knight RSG (2008) Systematic review of therapeutic interventions in human prion disease. Neurology 70:1272–1281PubMedCrossRefGoogle Scholar
  21. 21.
    Tagliavini F, McArthur RA, Canciani B, Giaccone G, Porro M, Bugiani M, Peri E, Dall’Ara P, Rocchi M et al (1997) Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 276:1119–1122PubMedCrossRefGoogle Scholar
  22. 22.
    Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E et al (2000) Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 300:1309–1322PubMedCrossRefGoogle Scholar
  23. 23.
    Trevitt CR, Collinge JA (2006) Systematic review of prion therapeutics in experimental models. Brain 129:2241–2246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Laura Colombo
    • 1
  • Paola Piovesan
    • 2
  • Orlando Ghirardi
    • 2
  • Mario Salmona
    • 1
  • Gianluigi Forloni
    • 1
  1. 1.Istituto di Ricerche Farmacologiche “Mario Negri”MilanItaly
  2. 2.R&D Laboratory Sigma Tau s.p.a.RomeItaly

Personalised recommendations